Ross Osborn
Stock Analyst at Cantor Fitzgerald
(1.74)
# 3,203
Out of 4,901 analysts
111
Total ratings
29.41%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings | Reiterates: Overweight | $7 | $4.35 | +60.92% | 3 | Jul 15, 2025 | |
| MDXG MiMedx Group | Reiterates: Overweight | $11 | $6.80 | +61.88% | 4 | Jul 15, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $6.51 | +84.33% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $7.29 | -3.91% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.15 | +73.91% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $9.14 | +86.00% | 6 | May 14, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $16.86 | +48.28% | 9 | May 6, 2025 | |
| NNOX Nano-X Imaging | Maintains: Overweight | $12 → $9 | $5.01 | +79.64% | 11 | Apr 1, 2025 | |
| SMTI Sanara MedTech | Reiterates: Overweight | $46 | $27.90 | +64.87% | 6 | Mar 26, 2025 | |
| ELUT Elutia | Reiterates: Overweight | $8 | $2.16 | +270.37% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $11.53 | +108.15% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.42 | +181.69% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $9 | $8.16 | +10.29% | 7 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.08 | +192.21% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $5.41 | +288.17% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $8.19 | +95.36% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $8.30 | +68.67% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $96 | $81.80 | +17.36% | 1 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.40 | +150.90% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.71 | +252.61% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.92 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.58 | +1,377.10% | 2 | Aug 18, 2023 |
Organogenesis Holdings
Jul 15, 2025
Reiterates: Overweight
Price Target: $7
Current: $4.35
Upside: +60.92%
MiMedx Group
Jul 15, 2025
Reiterates: Overweight
Price Target: $11
Current: $6.80
Upside: +61.88%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $6.51
Upside: +84.33%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $7.29
Upside: -3.91%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.15
Upside: +73.91%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $9.14
Upside: +86.00%
SI-BONE
May 6, 2025
Reiterates: Overweight
Price Target: $25
Current: $16.86
Upside: +48.28%
Nano-X Imaging
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $5.01
Upside: +79.64%
Sanara MedTech
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $27.90
Upside: +64.87%
Elutia
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $2.16
Upside: +270.37%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $11.53
Upside: +108.15%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.42
Upside: +181.69%
Jan 16, 2025
Reiterates: Overweight
Price Target: $9
Current: $8.16
Upside: +10.29%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $3.08
Upside: +192.21%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $5.41
Upside: +288.17%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $8.19
Upside: +95.36%
Oct 23, 2024
Reiterates: Overweight
Price Target: $14
Current: $8.30
Upside: +68.67%
Oct 15, 2024
Initiates: Neutral
Price Target: $96
Current: $81.80
Upside: +17.36%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.40
Upside: +150.90%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.71
Upside: +252.61%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.92
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.58
Upside: +1,377.10%